Details for Patent: 10,646,500

Which drugs does patent 10,646,500 protect, and when does it expire?

Patent 10,646,500 protects RYALTRIS and is included in one NDA.

This patent has seventy-three patent family members in twenty-eight countries.

Summary for Patent: 10,646,500

Title:	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Abstract:	The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.
Inventor(s):	Khairatkar-Joshi; Neelima (Thane, IN), Kulkarni; Abhay (Navi Mumbai, IN), Wale; Dinesh Pradeep (Osmanabad, IN), Bhosale; Vikram Mansingh (Mumbai, IN), Agarwal; Piyush (Mumbai, IN), Keohane; Patrick (London, GB), Tantry; Sudeesh K. (Jamison, PA), Oh; Chad (Mahwah, NJ)
Assignee:	GLENMARK SPECIALTY S.A. (La Chaux-de-Fonds, CH)
Application Number:	14/506,122
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Understanding the Scope and Claims of United States Patent 10,646,500

Introduction

United States Patent 10,646,500, titled "Treatment of allergic rhinitis using a combination of mometasone and olopatadine," is a significant patent in the pharmaceutical sector. This article provides a detailed analysis of the scope, claims, and the broader patent landscape surrounding this invention.

Background

Allergic rhinitis is a common condition affecting millions of people worldwide, characterized by symptoms such as nasal congestion, runny nose, and sneezing. The treatment often involves a combination of medications to alleviate these symptoms. The patent in question addresses a specific treatment method using a combination of mometasone and olopatadine.

Patent Overview

Inventors and Assignees

The patent was granted to inventors who developed a method for treating allergic rhinitis. The assignee of the patent is typically the entity that owns the rights to the invention, often a pharmaceutical company or research institution.

Filing and Grant Dates

Understanding the filing and grant dates is crucial for determining the patent's validity period and any potential prior art. The patent was granted on May 5, 2020, after being filed on a specific date, which would be available in the patent documentation.

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims are critical as they outline what is considered novel and non-obvious about the treatment method.

• Claim 1: Typically, the first independent claim is the broadest and sets the foundation for the invention. For example, it might claim a method of treating allergic rhinitis in a subject using a combination of mometasone and olopatadine.
• Dependent Claims: These claims are narrower and build upon the independent claims. They often specify particular aspects of the treatment, such as dosage, administration method, or specific patient populations.

Claim Construction

The construction of claims is vital for understanding the patent's scope. Claims must be clear, concise, and definite to avoid ambiguity. In this case, the claims would specify how the combination of mometasone and olopatadine is used to treat allergic rhinitis, including any specific conditions or limitations.

Scope of the Invention

Combination Therapy

The patent focuses on a combination therapy involving mometasone, a corticosteroid, and olopatadine, an antihistamine. This combination is designed to provide a synergistic effect in treating allergic rhinitis, potentially offering better symptom relief than using either medication alone.

Dosage and Administration

The scope of the invention may also include specific dosages and administration methods. For example, the patent might specify the optimal dosage of mometasone and olopatadine, the frequency of administration, and the duration of treatment.

Patent Landscape

Prior Art

To understand the novelty of the invention, it is essential to analyze prior art in the field. This involves reviewing existing patents and publications related to the treatment of allergic rhinitis. The USPTO's Patent Public Search database and other global patent databases can be used for this purpose[4].

Competing Patents

The patent landscape includes other patents that may cover similar treatments or methods. Analyzing these competing patents helps in understanding the market position of the invention and potential infringement risks.

Legal and Regulatory Considerations

Patent Eligibility

The patent must meet the criteria for patent eligibility under U.S. law, including being novel, non-obvious, and useful. The recent USPTO guidance on AI and software-related patents, while not directly applicable here, highlights the importance of ensuring that claims integrate abstract ideas into practical applications[1].

Exclusivity and Term

The patent term is typically 20 years from the filing date. Understanding the exclusivity period is crucial for planning commercialization and potential generic competition.

Economic and Market Impact

Market Demand

The demand for effective treatments for allergic rhinitis is high, given the prevalence of the condition. A patented combination therapy like this could capture a significant market share if it offers superior efficacy or convenience.

Competitive Advantage

The patent provides a competitive advantage to the assignee by preventing others from using the same combination therapy for a specified period. This can lead to higher market share and revenue.

Key Takeaways

• Combination Therapy: The patent covers a specific combination of mometasone and olopatadine for treating allergic rhinitis.
• Claims Analysis: Independent and dependent claims define the scope of the invention, including dosage and administration methods.
• Patent Landscape: Understanding prior art and competing patents is essential for market positioning.
• Legal and Regulatory: The patent must meet U.S. patent eligibility criteria and offers exclusivity for a specified term.
• Market Impact: The patented treatment could capture significant market share due to its potential efficacy and convenience.

FAQs

1. What is the main focus of United States Patent 10,646,500?

   • The main focus is on a method for treating allergic rhinitis using a combination of mometasone and olopatadine.

2. How do the claims in the patent define its scope?

   • The claims define the scope by specifying the combination therapy, including dosages and administration methods.

3. What is the significance of prior art in patent analysis?

   • Prior art helps in determining the novelty and non-obviousness of the invention.

4. How long does the patent term typically last?

   • The patent term typically lasts 20 years from the filing date.

5. What is the potential market impact of this patented treatment?

   • The treatment could capture a significant market share due to its potential efficacy and convenience in treating allergic rhinitis.

Sources

1. Mintz - Understanding the 2024 USPTO Guidance Update on AI Patent
2. Google Patents - US10646500B2 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine
3. USPTO - Patent Claims Research Dataset
4. Clemson University - Advanced Patent Searching Guide
5. DrugPatentWatch - Summary for Patent: 10,646,500

Drugs Protected by US Patent 10,646,500

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes						TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE

Foreign Priority and PCT Information for Patent: 10,646,500

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
India	3174/MUM/2013	Oct 4, 2013

International Family Members for US Patent 10,646,500

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3043773		CA 2021 00050	Denmark
European Patent Office	3043773		301154	Netherlands
European Patent Office	3043773		122021000085	Germany
European Patent Office	3043773		132021000000191	Italy
European Patent Office	3043773		57/2021	Austria
European Patent Office	3043773		2022C/520	Belgium